Overview

Study to Evaluate the Pharmacokinetics and Pharmacodynamics of AZD4604 Given Via the Turbuhaler Device in Adults With Mild Asthma.

Status:
COMPLETED
Trial end date:
2025-05-29
Target enrollment:
Participant gender:
Summary
The study will investigate the Pharmacokinetic (PK), Pharmacodynamic (PD), the safety and tolerability of AZD4604, as well as to examine the effect of Fractional exhaled Nitric Oxide (FeNO) following the administration of the multiple doses of AZD4604 via Turbuhaler device.
Phase:
PHASE1
Details
Lead Sponsor:
AstraZeneca